Novan Inc

Novan — Investor Presentation (February 2021)

23 slides from Novan's investor presentation, Feb 25, 2021

  1. Slide 1: Corporate Presentation

    Nitric Oxide-Based Medicine novan.com NASDAQ: NOVN Corporate Presentation February 24, 2021 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements including, but not limited to, statements related to the potential therapeutic value of our NITRICIL™ platform technology, our pharmaceutical development of nitric oxide-releasing product candidates, our intention to ad

  3. Slide 3: Ongoing pivotal Phase 3 study with data targeted before the end of Q2 2021

    Ongoing pivotal Phase 3 study with data targeted before the end of Q2 2021 3

  4. Slide 4: Investment Opportunity

    Investment Opportunity 4 Company’s First Potential NDA Filing Targeted No Later Than Q3 2022 NITRICIL™ Platform Significant Market Opportunity Pipeline Expansion Opportunities ~3.4 million1 Lead program, SB206 ongoing pivotal Phase 3 for treatment of molluscum Leveraging nitric oxide’s naturally occ

  5. Slide 5: Priority Development Pipeline

    Priority Development Pipeline 5 Product Candidate Indication Pre-IND Phase 1 Phase 2 Phase 3 Approval Program Highlight DERMATOLOGY SB206 Molluscum Target Reporting Topline Results before the end of Q2 2021 INFECTIOUS DISEASE SB019 Coronavirus First Demonstration of Antiviral Effect of NO Against SA

  6. Slide 6: NITRICIL™: Nitric oxide (NO) for therapeutic innovation

    NITRICIL™ Nitric oxide (NO) for therapeutic innovation 6

  7. Slide 7: Nitric Oxide (NO): Naturally Occurring Antiviral and Immunomodulatory Effects

    Nitric Oxide (NO) 7 Naturally Occurring Antiviral and Immunomodulatory Effects Colasanti, M. et al. S-Nitrosylation of Viral Proteins: Molecular Bases for Antiviral Effect of Nitric Oxide IUBMB Life; 1999 (48) 25-31. Kroen, KD. J Clin Invest. 1993;91(6):2446- 2452.; Karupiah, G; et al. Science. 1993

  8. Slide 8: Tunable Dosing Enables Proprietary Formulations That Target Each Indication

    8 Tunable Dosing Enables Proprietary Formulations That Target Each Indication NITRICIL™ Proprietary Nitric Oxide Based Technology Platform Generates Macromolecular New Chemical Entities (NCEs) 8006004002000 100 80 60 40 20 0 Time (min) % N O R el ea se NVN4428 NVN1000 t1/2 =2.3 min t1/2 =118 min Cum

  9. Slide 9: SB206: Lead Program

    SB206: Lead Program 9 Ongoing pivotal Phase 3 study for treatment of molluscum

  10. Slide 10: SB206: Berdazimer Sodium Topical Antiviral Gel

    10 New Chemical Entity Patients treated to date: >3,400 Compelling safety profile Macromolecule comprised of a polysiloxane backbone with covalently bound N-diazeniumdiolate NO donors SB206: Berdazimer Sodium Topical Antiviral Gel for the Treatment of Viral Skin Infections IP until 2035 Re al -T im

  11. Slide 11: No FDA-Approved Treatments for Molluscum

    11 No FDA-Approved TreatmentsMolluscum Contagious skin infection caused by the molluscipoxvirus, a double- stranded DNA virus Current treatment options are limited: • Off-label Rx/OTC• Physical procedures ~70% of patients below the age of 10 Average time to resolution 13 Months ~3.4 million prevalen

  12. Slide 12: Development Pathway Towards Potential Approval

    Development Pathway Towards Potential Approval 12 Potential NDA Filing Targeted No Later Than Q3 2022 B-SIMPLE2 Completed B-SIMPLE4 Topline Results Targeted Q2 2021 B-SIMPLE1 Completed Key findings from immense body of data and external experts guided the design of the B-SIMPLE program 352 Subject

  13. Slide 13: B-SIMPLE1 and B-SIMPLE2 Integrated Analysis

    B-SIMPLE1 and B-SIMPLE2 13 Integrated Analysis Demonstrated Statistically Significant (p=0.038) Complete Clearance Rate (27.9%) vs. Vehicle (20.9%) at Week 12 B-SIMPLE1: 352 Subjects B-SIMPLE2: 355 Subjects 0.0% 4.3% 10.3% 21.6% 0.4% 4.7% 15.3% 25.8% 0% 5% 10% 15% 20% 25% 30% 35% Week 2 Week 4 Week

  14. Slide 14: B-SIMPLE4 Pivotal Phase 3 Study Design in Molluscum

    Treatment 12 Weeks Follow-up at Week 24 14 B-SIMPLE4 Pivotal Phase 3 Study Design in Molluscum Study Design Based on Learnings from B-SIMPLE1 and B-SIMPLE2: One and two-subject household stratification Inflammation of molluscum lesions added as a stratification factor1 Additional patient and caregiv

  15. Slide 15: SB206 Commercialization Strategy

    SB206 Commercialization Strategy 15 Preparing for Success Evaluating All Strategic Options Novan Commercializes Secure Commercialization Partner Co-Commercialize with Partner

  16. Slide 16: Coronavirus (COVID-19) Program

    16 Coronavirus (COVID-19) Program Potential IND filing targeted in 2021 Results from in vitro assessment of concentrations as low as 0.75 mg/mL demonstrated berdazimer sodium reduced 90% of virus after repeat dosing, once daily Engaged Catalent, a global leader in providing integrated services, supe

  17. Slide 17: Companion Animal Health Program

    Companion Animal Health Program 17 Commenced Exploratory Work to Evaluate NO Application in Adjacent Market Engaged third-party animal health experts to determine technical feasibility and market potential Initial formulation development to assess viability in progress Upon positive proof of concept

  18. Slide 18: Pipeline Expansion Opportunities

    Pipeline Expansion Opportunities 18 Ongoing In-Depth Review for Pipeline Prioritization Product Candidates Indication Pre-IND Phase 1 Phase 2 Phase 3 Program Highlight DERMATOLOGY SB204 Acne Vulgaris Two Phase 3’s completed; One confirmatory Phase 3 needed; Protocol finalized SB208 Tinea Pedis Phase

  19. Slide 19: Corporate Overview

    Corporate Overview 19

  20. Slide 20: Financial Profile

    Financial Profile Nasdaq: NOVN 20 1. Out of 200,000,000 total common stock authorized per certificate of incorporation. 2. Based on February 10, 2021 closing price of $1.96. 3. Based on Management’s projections and planned development and operating activities described in the Company’s December 31,

  21. Slide 21: Upcoming Targeted Milestones

    Upcoming Targeted Milestones 21  September 2020: Selection of NCE for Animal Health Pipeline  October 2020: Coronavirus - Reported Results Demonstrating In Vitro Antiviral Effect  September 2020: First Patient Dosed  September 2020: Commenced Study  February 2021: Completed Enrollment SB206 B-S

  22. Slide 22: Near Term Inflection Point: Broad Pipeline

    Near Term Inflection Point: Broad Pipeline 22 Topline Results From Pivotal B-SIMPLE4 Phase 3 Study in Molluscum Targeted Before the End of Q2 2021 Proprietary NITRICIL™ Platform: Harnessing the antiviral and immunomodulatory power of nitric oxide Fueling a pipeline with multiple growth opportunities

  23. Slide 23: Investor Relations

    Nitric Oxide-Based Medicine Investor Relations JTC Team 833.475.8247 novn@jtcir.com novan.com NASDAQ: NOVN

Novan — Investor Presentation (February 2021) on 6ix